Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Omecamtiv mecarbil

- PMLiVE

Amgen raises forecasts after closing $13.4bn Otezla deal

Scope to build product further with ongoing trials in additional indications

China flag thumb

Amgen buys BeiGene stake for $2.7bn to aid push into China

China's oncology market forecast to nearly double in size by 2026

- PMLiVE

Amgen exits neuroscience R&D to focus on growth areas

Move has resulted in loss of around 180 jobs

- PMLiVE

New hires at Amgen, Eli Lilly and Zosano

The latest movers in pharma

AstraZeneca AZ

AZ’s Farxiga gets heart failure prevention okay from FDA

Important win for AZ as it chases down market leader Jardiance

- PMLiVE

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

Initially received a negative opinion of the drug

- PMLiVE

Servier faces manslaughter trial over weight loss drug deaths

Drug shown to damage heart and thought to cause death

- PMLiVE

New data backs GeNeuro’s MS drug after Servier exit

Search continues for new development partner

AstraZeneca AZ

FDA fast-tracks AstraZeneca’s Farxiga in heart failure

Races to become first-in-class

- PMLiVE

Amgen reveals more data on KRAS drug

Unveiled an overall disease control rate of 100%

- PMLiVE

Amgen takes aim at Alexion’s patents for Soliris

Follows extension of Soliris patent protection until 2027

- PMLiVE

Amgen snaps up Celgene’s Otezla for $13.4bn

Higher-than-expected price helps BMS sweeten merger deal

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links